Germany

The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).

The company grew revenue by 10% to EUR 1.75 billion (USD1.91 billion) while substantially improving profitability and cash generation.

The Maisons-Alfort plant, which previously operated under Sanofi’s ownership, specializes in fill-finish manufacturing at commercial scale.

Results confirmed that Caas vFFR is a safe and effective alternative to conventional pressure wire-based physiology for guiding treatment decisions in patients with intermediate coronary artery stenosis.

The transaction, which remains subject to customary regulatory approvals, marks the beginning of what both firms describe as Syntegon’s next major growth phase.

Construction crews have already broken ground on the expansion project, which Axplora expects to complete by February 2027.

LYOCONTRACT has partnered with Syntegon, a leading equipment supplier, to install a complete filling and lyophilization line at the new facility.

The company showcased three new angiography platforms—Artis genio, Artis icono.explore, and Artis icono.vision—which harness artificial intelligence to enhance the precision of liver cancer embolization treatments.

The platform integrates visual inspection capabilities with advanced leak detection technology, processing up to 600 vials per minute while maintaining rigorous quality standards.

The company plans to use the funding primarily to support a phase 2 clinical study evaluating Deraphan, its experimental treatment for agitation in patients with Alzheimer’s disease.